Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 10/20 | 0.45 |
| ▸ | PTGES | O14684 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR1E | P28566 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10006477 | 1.00 | ACKR3 (0.45) | ACKR3PTGESMEN1LMNAHTR1E | |
| SCHEMBL10006452 | 1.00 | ACKR3 (0.45) | ACKR3PTGESMEN1LMNAHTR1E | |
| SCHEMBL10006303 | 0.91 | PTGES (0.46) | ACKR3PTGESMEN1LMNAHTR1E | |
| SCHEMBL11932110 | 0.88 | ACKR3 (0.41) | ACKR3PTGESMEN1KMT2APTGS2 | |
| SCHEMBL10006274 | 0.88 | PTGES (0.43) | ACKR3PTGESKMT2APTGS2CNR1 | |
| Bicarbonate SCHEMBL16735562 | 0.86 | ACKR3 (0.47) | ACKR3PTGESMEN1LMNAHTR1E | |
| Bicarbonate SCHEMBL16735555 | 0.86 | ACKR3 (0.47) | ACKR3PTGESMEN1LMNAHTR1E | |
| Bicarbonate SCHEMBL16735577 | 0.86 | ACKR3 (0.47) | ACKR3PTGESMEN1LMNAHTR1E | |
| SCHEMBL10006296 | 0.86 | PTGES (0.56) | ACKR3PTGESMEN1LMNAHTR1E | |
| SCHEMBL10006307 | 0.86 | PTGES (0.56) | ACKR3PTGESMEN1LMNAHTR1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649045-B1 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2649045-B1 | SUBSTITUTED 1-BENZYLCYCLOALKYLCARBOXLIC ACIDS AND USE THEREOF | BAYER IP GMBH (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-9018258-B2 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172448-A1 | Substituted 1-benzylcycloalkylcarboxylic acids and the use thereof | PC, ACACA, PCCA | ACKR3 3131/4885PTGES 1094/4885MEN1 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.